Syria vs Western Pacific (WHO region): Hepatitis B surface antigen (HBsAg) prevalence (%)
Syria
2.9%
in 2024
Western Pacific (WHO region)
0.4%
in 2024
Syria rank
6th
Western Pacific (WHO region) rank
6th
Hepatitis B surface antigen (HBsAg) prevalence (%) over time
- Syria
- Western Pacific (WHO region)
How they compare
Syria currently reports 2.9% against 0.4% in Western Pacific (WHO region), a difference of 2.5%.
That makes Syria's figure about 7.2 times Western Pacific (WHO region)'s.
Across all 10 years both countries report, Syria has been ahead every year.
Syria ranks 6th and Western Pacific (WHO region) ranks 6th of 194 countries.
Syria has averaged higher in every one of the 2 decades both report.
Head to head by decade
| Decade | Syria | Western Pacific (WHO region) | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 3.5% | 0.4% | 3.1% | Syria |
| 2020s | 3.4% | 0.4% | 3.0% | Syria |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher hepatitis b surface antigen (hbsag) prevalence, Syria or Western Pacific (WHO region)?
- Syria, at 2.9% against 0.4% in Western Pacific (WHO region) as of 2024.
- What is the difference in hepatitis b surface antigen (hbsag) prevalence between Syria and Western Pacific (WHO region)?
- 2.5%, with Syria ahead.
- How many years of comparable data are there for Syria and Western Pacific (WHO region)?
- 10 years are reported by both, from 2015 to 2024.
- How do Syria and Western Pacific (WHO region) rank globally for hepatitis b surface antigen (hbsag) prevalence?
- Syria ranks 6th and Western Pacific (WHO region) ranks 6th of 194 countries.
- Where does this data come from?
- World Health Organization, Global Health Observatory, published as Hepatitis B surface antigen (HBsAg) prevalence (%). Statizoid refreshes it automatically from the source and publishes the full history for both places.